Upstream Bio, Inc. (NASDAQ: UPB ) is among the best low priced stocks to get rich in 2026 . On June 12, JPMorgan significantly trimmed the price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35, while downgrading the stock from Overweight to Neutral. In a research note, the analyst said that other peers in asthma are also set to generate new data over the course of the company's Verekitug's late-stage development. Thus, the results from these competitors are important to understand where the company's product stands.
According to JPMorgan, the rest of the year and beyond appear as an execution period for the company, with "relatively sparse near-term stock-moving catalysts." The firm finds it difficult to see a path to upside in the near term, especially given the company's additional cash needs to power phase 3 development. The company's negative returns are understandable, considering its 572% upside potential. With strong potential for future gains, Upstream Bio, Inc. (NASDAQ:UPB) is among the best low-priced stocks to get rich in 2026.
Copyright: dolgachov / 123RF Stock Photo
Back on June 3, Matthew Caufield from H.C. Wainwright began coverage of Upstream Bio, Inc. (NASDAQ:UPB) with a Buy rating and $36 price target. The analyst believes Verekitug is a novel antibody antagonist of the thymic stromal lymphopoietin receptor, with "sights on efficacy and differentiated quarterly subcutaneous dosing."
Upstream Bio, Inc. (NASDAQ:UPB), incorporated in 2021, is a Massachusetts-based clinical-stage biotechnology company specializing in solutions for severe respiratory disorders.
While we acknowledge the potential of UPB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News .
